Vor Biopharma (VOR) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 3[1].
Trial NCT06456580[3] evaluates Telitacicept in Generalized Myasthenia Gravis with a target enrollment of 180 participants. Trial NCT07404865[4] evaluates Telitacicept in Primary Sjogren's Disease with a target enrollment of 250 participants.
VOR has 2 Form 4 insider filings recorded at the SEC in the past 30 days[5].